{
    "body": "Is dichlorphenamide effective for periodic paralysis?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/3374500", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18345024", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6855804", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18426576", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10632100", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19019313", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18254068"
    ], 
    "ideal_answer": [
        "Yes, dichlorphenamide is effective for periodic paralysis. Dichlorphenamide--a carbonic anhydrase inhibitor--has been shown in a controlled trial to prevent attacks for many patients with both hypokalemic and hypokalemic periodic paralysis."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.biosemantics.org/jochem#4249177", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004005"
    ], 
    "type": "yesno", 
    "id": "56c1d841ef6e39474100002d", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 177, 
            "text": "BACKGROUND AND PURPOSE: Acetazolamide and dichlorphenamide are carbonic anhydrase (CA) inhibitors effective in the clinical condition of hypokalemic periodic paralysis (hypoPP).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18345024", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1320, 
            "offsetInEndSection": 1866, 
            "text": "In one study dichlorphenamide (DCP) vs placebo was tested in two groups of participants: 42 with hypokalemic periodic paralysis (HypoPP) and 31 with hyperkalemic periodic paralysis (HyperPP), based on clinical criteria. Thirty-four of 42 participants with hypokalemic periodic paralysis completed both treatment phases. For the 34 participants having attack rate data for both treatment phases, the mean improvement in attack rate (P = 0.02) and severity-weighted attack rate (P = 0.01) on DCP relative to placebo were statistically significant. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18254068", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2550, 
            "offsetInEndSection": 2759, 
            "text": "AUTHORS' CONCLUSIONS: The largest included study that met our inclusion criteria suggested that DCP was effective in the prevention of episodic weakness in both hypokalemic and hyperkalemic periodic paralyses.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18254068", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 606, 
            "offsetInEndSection": 812, 
            "text": "For periodic paralysis, dichlorphenamide--a carbonic anhydrase inhibitor--has been shown in a controlled trial to prevent attacks for many patients with both hypokalemic and hypokalemic periodic paralysis. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19019313", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 709, 
            "offsetInEndSection": 858, 
            "text": "Chronically, acetazolamide, dichlorphenamide, or potassium-sparing diuretics decrease attack frequency and severity but are of little value acutely. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18426576", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 951, 
            "offsetInEndSection": 1373, 
            "text": " In the HypoPP trial, there were 13 subjects who exhibited a preference (in terms of the end point) for either DCP or placebo, and 11 of these preferred DCP. In the PSPP trial, DCP significantly reduced attack rates relative to placebo. DCP also significantly reduced attack rates relative to placebo in the HypoPP subjects. We conclude that DCP is effective in the prevention of episodic weakness in both HypoPP and PSPP.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/10632100", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 302, 
            "offsetInEndSection": 418, 
            "text": "Diclofenamid has now already been administered for 2 years. It is well tolerated and has suppressed further attacks.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/3374500", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 428, 
            "text": "Three patients with Hypokalemic Periodic Paralysis (HOPP)-associated progressive interattack muscle weakness, who became unresponsive or worsened by acetazolamide, responded favorably to dichlorophenamide, a more potent carbonic anhydrase inhibitor. Dichlorophenamide in single-blind placebo-controlled trials, considerably improved functional strength in two of the patients and had a moderate but definite effect in the third.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/6855804", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1046, 
            "offsetInEndSection": 1254, 
            "text": "Dichlorophenamide should be considered as an alternate to acetazolamide in the treatment of patients with HOPP-associated interattack muscle weakness who have become unresponsive or worsened by acetazolamide.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/6855804", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 153, 
            "text": "Acetazolamide and dichlorphenamide are carbonic anhydrase (CA) inhibitors effective in the clinical condition of hypokalemic periodic paralysis (hypoPP).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18345024", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 808, 
            "offsetInEndSection": 1013, 
            "text": "For periodic paralysis, dichlorphenamide--a carbonic anhydrase inhibitor--has been shown in a controlled trial to prevent attacks for many patients with both hypokalemic and hypokalemic periodic paralysis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19019313", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 277, 
            "text": "BACKGROUND AND PURPOSE: Acetazolamide and dichlorphenamide are carbonic anhydrase (CA) inhibitors effective in the clinical condition of hypokalemic periodic paralysis (hypoPP). Whether these drugs prevent vacuolar myopathy, which is a pathogenic factor in hypoPP, is unknown. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18345024", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 154, 
            "text": "Acetazolamide and dichlorphenamide are carbonic anhydrase (CA) inhibitors effective in the clinical condition of hypokalemic periodic paralysis (hypoPP).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18345024", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 607, 
            "offsetInEndSection": 916, 
            "text": "For periodic paralysis, dichlorphenamide--a carbonic anhydrase inhibitor--has been shown in a controlled trial to prevent attacks for many patients with both hypokalemic and hypokalemic periodic paralysis. A second trial, comparing dichlorphenamide with acetazolamide versus placebo, is currently in progress.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19019313", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 428, 
            "offsetInEndSection": 812, 
            "text": "Despite our better understanding of the pathogenesis of these disorders, current treatments are largely empirical and the evidence in favor of specific therapy largely anecdotal. For periodic paralysis, dichlorphenamide--a carbonic anhydrase inhibitor--has been shown in a controlled trial to prevent attacks for many patients with both hypokalemic and hypokalemic periodic paralysis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19019313", 
            "endSection": "abstract"
        }
    ]
}